Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported mandated share sales to cover taxes from vesting restricted stock units. Over March 17–19, she sold a total of 1,144 shares of common stock in open-market transactions, including 390 shares at $67.0000 per share and 379 shares at $68.7100 per share.
According to the disclosure, these “sell to cover” trades were required under the company’s tax withholding election and were not discretionary. After the transactions, Yeu directly held 23,308 common shares, with additional indirect holdings of 6,360 shares through her spouse’s Roth IRA and 12,040 shares through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported selling 6,430 shares of common stock in open‑market transactions over three days. He sold 2,111 shares at $69.42, 2,133 shares at $68.71, and 2,186 shares at $67.00 per share.
According to the disclosure, these sales were mandated "sell to cover" transactions to fund tax withholding obligations from vesting restricted stock units, rather than discretionary trades. After the sales, Farrow directly holds 43,316 Tarsus shares.
Tarsus Pharmaceuticals, Inc. President, CEO and Board Chair Bobak R. Azamian reported selling 34,603 shares of common stock in open-market transactions over three days at prices ranging from $67.00 to $69.42 per share. These sales were executed solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units under a mandated "sell to cover" arrangement, rather than as discretionary trades.
Following the transactions, he directly holds 33,421 common shares. He also serves as trustee of the Bobak Azamian Living Trust, which holds an additional 857,991 common shares over which he has voting and dispositive power.
TARS submitted a Form 144 to sell 2,186 shares of Common stock. The notice lists Fidelity Brokerage Services LLC as broker with a sale date of 03/19/2026. The filing also shows a restricted stock vesting event on 03/18/2026 for 2,186 shares and prior reported sales of 2,111 and 2,133 on 03/17/2026
Aziz A. Mottiwala files a Form 144 notifying a planned sale of 4,440 shares of Common Stock. The filing links the shares to restricted stock vesting dated 03/18/2026 and records two recent dispositions: 4,286 shares on 03/17/2026 and 4,330 shares on 03/18/2026.
The Form 144 names Fidelity Brokerage Services LLC as the broker-dealer. The filing characterizes the 4,440 shares as compensation-related restricted stock that vested on 03/18/2026.
TARS filed a Form 144 reporting proposed sales tied to recently vested restricted common stock and recent dispositions by an insider. The filing lists 11,964 shares associated with restricted stock vesting on 03/18/2026 and shows prior sales by Bobak Azamian of 10,972 shares on 03/17/2026 and 11,667 shares on 03/18/2026, with dollar amounts shown alongside each sale.
Dianne C. Whitfield filed a Form 144 reporting proposed sales of Common Stock. The filing lists three transactions: 15,565 shares on 01/02/2026 (proceeds $1,255,687.45), 4,029 shares on 03/17/2026 (proceeds $279,671.82), and 4,071 shares on 03/18/2026 (proceeds $279,717.60).
The broker on the notice is Fidelity Brokerage Services LLC. The filing includes a separate line noting Restricted Stock Vesting dated 03/18/2026.
TARS filed a Form 144 reporting proposed sale of 4,231 shares of Common Stock. The filing also records recent dispositions by Bryan Wahl of 4,084 shares on 03/17/2026 and 4,125 shares on 03/18/2026, with dollar entries of 283,489.63 and 283,427.93 respectively.
The notice lists a brokerage holder, Fidelity Brokerage Services LLC, and identifies a 03/18/2026 restricted stock vesting classified as Compensation. This Form 144 is a routine disclosure of intended resale under Rule 144 and related recent insider dispositions.
TARS filed a Form 144 reporting proposed sales of Common Stock by a reporting person. The filing lists 4,589 shares to be sold following a restricted stock vesting on 03/18/2026 as compensation. It also discloses prior sales in March: 8,366, 3,125, and 3,610 shares with associated proceeds reported.
TARS reported a Rule 144 notice for the proposed sale of 390 shares of Common Stock tied to a restricted stock vesting on 03/18/2026. The filing lists prior short-term transactions by Elizabeth Yeu-Lin: 375 shares on 03/17/2026 and 379 shares on 03/18/2026.
The filing identifies Fidelity Brokerage Services LLC as the broker and labels the 390-share entry as compensation-related (restricted stock vesting). This notice is an administrative disclosure of an intended resale under Rule 144.